
The factors associated with treatment outcomes in Alzheimer's disease (AD) patients after 1 year of acetylcholinesterase inhibitor (AChEI) treatment were examined. The study included 1370 participants aged 60 or older who were newly diagnosed with AD and prescribed AChEIs. Cognitive assessments were used to define cognitive progressors before and after 1 year of AChEI treatment. The results indicated that a lower body mass index (BMI) and concurrent use of antipsychotics and benzodiazepine receptor agonists were associated with a higher likelihood of cognitive decline in AD patients receiving 1 year of AChEI treatment. Specifically, lower BMI, higher antipsychotic usage, and a tendency for increased benzodiazepine receptor agonist usage were linked to cognitive decline.
Like
Save
Share